Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
Status:
Completed
Trial end date:
2012-12-05
Target enrollment:
Participant gender:
Summary
This study will assess the effect of 26 weeks of once-weekly treatment with
MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600)
on serum levels of 25-hydroxyvitamin D [25(OH)D].
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Alendronate Cholecalciferol Ergocalciferols Vitamin D Vitamins